Gwendolyn Knowlton Binder-Scholl, Chief Technology Officer at Adaptimmune Therapeutics PLC (ADAP), sold 1,514 shares at $5.37 ($8K) on 2019-01-14, disclosed to the SEC on 2019-01-16.
Open-market sale of $8k ADAP by Chief Technology Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |